Trial Profile
Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 09 Aug 2016
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Proof of concept; Therapeutic Use
- 04 Aug 2016 Status changed from active, no longer recruiting to discontinued.
- 11 May 2016 Status changed from recruiting to active, no longer recruiting.
- 04 Sep 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.